Giving triglycerides their due

Hospital Practice

Volumn 34, Issue 9, 1999, Pages 67-73

  Miller, Michael ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033198838     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.3810/hp.1999.09.1.162     Document Type: Article

References (8)

1. Austin MA et al: Atherogenic lipoprotein phenotype: A proposed genetic marker for coronary heart disease risk. Circulation 82:495, 1990
2. Chait A et al: Susceptibility of small, dense, low-density lipoproteins to oxidative modification In subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94:350, 1993
3. Glanturco SH, Bradley WA: Pathophyslology of triglyceride-rich lipoproteins in atherothrombosis: Cellular aspects. Clin Cardlol 22(Suppl II):7, 1999
4. Hamsten A et al: Increased plasma levels of a rapid Inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313:1557, 1985
5. Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease Independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:231, 1996
6. Miller M et al: Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study (COLTS). J Am Coll Cardlol 31:1252, 1998
7. Otvos J: Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardlol 22(Suppl II):21, 1999
8. Segal A et al: Hypertriglyceridaemia and vascular risk: Report of a meeting of physicians and scientists, University College of London Medical School. Lancet 342:781, 1993